Nkarta, Inc. (NKTX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Nkarta’s loss per share was wider than expected in the third fiscal quarter of 2026, with EPS of -$0.45 trailing the -$0.40 estimate by -$0.05, based on preliminary results reported November 10, 2026. Net loss widened to about -$33.3 million, down -53.5% year over year from roughly -$21.7 million a year ago, while EPS declined -55.2% from -$0.29 in the prior-year quarter. Operating income was about -$35.8 million, and the company generated negative operating cash flow of roughly -$25.8 million. Consensus for the next period calls for EPS of -$0.42.
About Nkarta, Inc.
Nkarta, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector developing cell therapies built from natural killer cells, with work aimed at treating cancer and autoimmune disease. In qualitative terms, it is a clinical-stage biotech, and the company went public in 2020.
Today's Snapshot
The day ended with NKTX 6.4% lower at 1.17, in line with a weaker sector. Shares changed hands at about a third of its usual level.
Trading Volume
Below 10d avg (2.0M)
685.1K
vs S&P 500 Today
Strong Underperformance
-6.14%
Updated: November 18, 2026 at 21:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.34 - $2.28Sell
- RSI (14)30.49Neutral
- Stochastic %K (14, 3, 3)12.79Buy
- MACD Level (12, 26)-0.24Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.